Babelova et al., "Monoamine oxidases
are mediators of endothelial dysfunction in the mouse aorta," Hypertension, vol.
(MAO) is an enzyme that reduces neurotransmitters to their metabolites for excretion, thus providing an essential component of the normal cycle of transmitter production and excretion.
This could have been anticipated since inhibition of monoamine oxidase
leads to increased availability of norepinephrine and serotonin besides dopamine.
A is the main enzyme in the brain that breaks down serotonin, norepinephrine and dopamine, which have been shown to contribute to the "fight or flight" impulse by raising heart rates and increasing blood and oxygen flow.
(MAO) and some other brain neurotransmitters play a complicated role in the development of female sexual dysfunction symptoms.
(1.) Balon R, Mufti R, Arfken CL A survey of prescribing practices for monoamine oxidase
Masini et al., "Oxidative stress by monoamine oxidase
mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury," Circulation, vol.
DA is converted to DOPAC intraneuronally after re-uptake, whereas extraneuronal DA is converted to HVA by the enzymes catechol-O-methyltransferase and monoamine oxidase
. The lack of change in DOPAC and HVA could reflect the relatively modest nature of the changes in DA, leaving a sufficiently high concentration of DA in the intracellular space to maintain constant levels of DOPAC and HVA production.
WASHINGTON -- A transdermal patch containing the selective monoamine oxidase
inhibitor selegiline applied daily appeared effective and well tolerated in a pilot study of children and adolescents with attention-deficit hyperactivity disorder.
Most of these medications effectively treat depression by increasing available levels of monoamine neurotransmitters through monoamine oxidase
inhibition, reuptake inhibition, or neurotransmitter binding.
Researchers at Birmingham University looked at 17 trials involving a group of drugs called monoamine oxidase
type B inhibitors (MAOBIs), which are used to slow the progression of Parkinson's.
Weight gain is seen with SSRIs but is more common with tri-cyclic antidepressants, monoamine oxidase
inhibitors, and mirtazapine.